Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Peter Caravan
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Reveal Pharmaceuticals
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Caravan owns private equity in the above mentioned interest that is specialized in developing a new MRI contrast that is manganese based, an alternative to MRI contrasts that contain Gadolinium. This grant will use and develop a new MRI technology that can prepare an MRI probe in the contrast for imaging kidneys for renal disease. The above mentioned company could have an interest in IP resulting from research under this grant. Based on the magnitude of this financial interest and the close connection between the company's interests and the research, the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
Molecular Imaging of Renal Fibrogenesis
Renal fibrosis is the final common pathway for virtually all chronic kidney diseases and is often a precursor to end-stage renal disease (ESRD), a devastating disorder that requires dialysis or kidney transplantation. The goal of this project is o develop a new magnetic resonance imaging (MRI) probe to noninvasively detect and quantify renal fibrosis, as well as monitor whether new therapies for renal fibrosis are effective.
Filed on December 08, 2016.
Tell us what you know about Peter Caravan's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Peter Caravan filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Reveal Pharmaceuticals | $150,000 - $199,999 |
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Collagen Medical, LLC | $20,000 - $39,999 |
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Reveal Pharmaceuticals | Value cannot be readily determined |
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Collagen Medical, LLC | Value cannot be readily determined |
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Reveal Pharmaceuticals | Value cannot be readily determined |
| Peter Caravan | Massachusetts General Hospital | Conflict of Interest | Factor 1A, LLC | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.